Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2016-11-01
|
| Series: | South African Family Practice |
| Subjects: | |
| Online Access: | https://safpj.co.za/index.php/safpj/article/view/4524 |
| _version_ | 1818756393604218880 |
|---|---|
| author | M. O.E. Irhuma M. Vally |
| author_facet | M. O.E. Irhuma M. Vally |
| author_sort | M. O.E. Irhuma |
| collection | DOAJ |
| description | Heart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a growing public health problem. Pathophysiologically, heart failure clinically presents in two common forms: heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. The cornerstone of heart failure management includes the use of angiotensin-converting enzyme inhibitors. A recently developed pharmacotherapy that inhibits both the angiotensin receptor and the enzyme neprilysin has shown promise in the management of heart failure with reduced ejection fraction. This article will highlight the impact of this new therapy and its potential use in heart failure with reduced ejection fraction. |
| first_indexed | 2024-12-18T05:54:20Z |
| format | Article |
| id | doaj.art-801839061dbb4212a01f2e4dfd12d184 |
| institution | Directory Open Access Journal |
| issn | 2078-6190 2078-6204 |
| language | English |
| last_indexed | 2024-12-18T05:54:20Z |
| publishDate | 2016-11-01 |
| publisher | AOSIS |
| record_format | Article |
| series | South African Family Practice |
| spelling | doaj.art-801839061dbb4212a01f2e4dfd12d1842022-12-21T21:18:50ZengAOSISSouth African Family Practice2078-61902078-62042016-11-01585606310.4102/safp.v58i5.45243671Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shiftM. O.E. Irhuma0M. Vally1Division of Clinical and Experimental Pharmacology, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of Witwatersrand, JohannesburgDivision of Clinical and Experimental Pharmacology, Department of Pharmacy and Pharmacology, School of Therapeutic Sciences, Faculty of Health Sciences, University of Witwatersrand, JohannesburgHeart failure is a clinical syndrome responsible for at least one-third of hospitalisations amongst cardiac patients, with escalating mortality and healthcare costs on both public and private health care. Both prevalence and incidence of heart failure increase steeply with advancing age, making it a growing public health problem. Pathophysiologically, heart failure clinically presents in two common forms: heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. The cornerstone of heart failure management includes the use of angiotensin-converting enzyme inhibitors. A recently developed pharmacotherapy that inhibits both the angiotensin receptor and the enzyme neprilysin has shown promise in the management of heart failure with reduced ejection fraction. This article will highlight the impact of this new therapy and its potential use in heart failure with reduced ejection fraction.https://safpj.co.za/index.php/safpj/article/view/4524ace-inhibitorsangiotensin receptor blockersarbsenalaprilheart failurehfref managementneprilysin inhibitorssacubitrilvalsartan |
| spellingShingle | M. O.E. Irhuma M. Vally Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift South African Family Practice ace-inhibitors angiotensin receptor blockers arbs enalapril heart failure hfref management neprilysin inhibitors sacubitril valsartan |
| title | Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift |
| title_full | Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift |
| title_fullStr | Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift |
| title_full_unstemmed | Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift |
| title_short | Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift |
| title_sort | use of angiotensin receptor neprilysin inhibitors in heart failure a paradigm shift |
| topic | ace-inhibitors angiotensin receptor blockers arbs enalapril heart failure hfref management neprilysin inhibitors sacubitril valsartan |
| url | https://safpj.co.za/index.php/safpj/article/view/4524 |
| work_keys_str_mv | AT moeirhuma useofangiotensinreceptorneprilysininhibitorsinheartfailureaparadigmshift AT mvally useofangiotensinreceptorneprilysininhibitorsinheartfailureaparadigmshift |